Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

It is unclear whether targeted agents can produce survival advantage in patients with advanced HCC previously treated with sorafenib. We performed this meta-analysis of randomized trials and reviewed clinical outcomes of molecular targeted agents in the second-line treatment for advanced HCC. A syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Han, Kim, Bum Jun, Jang, Hyun Joo, Lee, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731957/
https://www.ncbi.nlm.nih.gov/pubmed/29254247
http://dx.doi.org/10.18632/oncotarget.21454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731957/
https://www.ncbi.nlm.nih.gov/pubmed/29254247
http://dx.doi.org/10.18632/oncotarget.21454

Ejemplares similares